Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | MITF | O75030 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3195522 | 1.00 | MAPT (0.45) | MAPTATMMITFALDH1A1LMNA | |
| SCHEMBL3191696 | 1.00 | MAPT (0.45) | MAPTATMMITFALDH1A1LMNA | |
| SCHEMBL3195461 | 0.95 | ATM (0.45) | MAPTATMMITFALDH1A1LMNA | |
| SCHEMBL3185860 | 0.95 | ATM (0.45) | MAPTATMMITFALDH1A1LMNA | |
| SCHEMBL3186469 | 0.90 | RXFP1 (0.45) | MAPTMITFALDH1A1LMNAHTT | |
| SCHEMBL3189925 | 0.89 | ATM (0.45) | MAPTATMALDH1A1RAB9AMDM2 | |
| SCHEMBL3191114 | 0.89 | TSHR (0.47) | MAPTATMMITFALDH1A1LMNA | |
| SCHEMBL3185790 | 0.88 | MAPT (0.43) | MAPTATMMITFALDH1A1LMNA | |
| SCHEMBL3191670 | 0.86 | MAPT (0.41) | MAPTMITFALDH1A1LMNAHTT | |
| SCHEMBL3187031 | 0.86 | ATM (0.47) | MAPTATMALDH1A1RAB9AMDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7671069-B2 | Tricyclic, heteroaromatic compounds modulating CXCR4 and/ or CXCR7 | CHEMOCENTRYX, INC. (US) | 2010-03-02 | — | — | US | disclosed |
| US-20070254915-A1 | CXCR4 MODULATORS | CHEMOCENTRYX, INC. (US) | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254915-A1 | CXCR4 MODULATORS | CXCL12, CXCR4, CXCR1 | MAPT 2809/4885ATM 3561/4885MITF 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.